CISH and neoplasm: In vivo, 100% Cish−/−, 100% Cish+/+ or 50/50 competitive chimeras were challenged with the MCA1956 cell line, and tumor burden was decreased in both the Cish-deficient chimeras as well as the competitive chimeras (Figure 6D).